BLUE JET HEALTHCARE Q2 FY27 CONCALL: EXPECTS GROSS MARGIN RECOVERY FROM Q3 FY27 AS CUSTOMER PRICE HIKES TAKE EFFECT; MAHAD UNIT 3 COMMISSIONING TARGETED IN H2 FY27, VIZAG PHASE 1 ENVISAGES ₹1,000 CR CAPEX & ₹800 CR QIP DEPLOYMENT OVER 3 YEARS; PI/API & CONTRAST MEDIA TO DRIVE GROWTH, WITH PEPTIDES AND CDMO EXPANSION